WO2023150820A1 - Procédé de synthèse de polymères biologiques radiomarqués - Google Patents
Procédé de synthèse de polymères biologiques radiomarqués Download PDFInfo
- Publication number
- WO2023150820A1 WO2023150820A1 PCT/AU2022/050088 AU2022050088W WO2023150820A1 WO 2023150820 A1 WO2023150820 A1 WO 2023150820A1 AU 2022050088 W AU2022050088 W AU 2022050088W WO 2023150820 A1 WO2023150820 A1 WO 2023150820A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- process according
- polycarboxylate
- buffer
- vessel
- biological polymer
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 115
- 230000008569 process Effects 0.000 title claims abstract description 104
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 13
- 238000003786 synthesis reaction Methods 0.000 title claims abstract description 12
- 229920000642 polymer Polymers 0.000 title claims description 37
- 229920005646 polycarboxylate Polymers 0.000 claims abstract description 63
- 238000006243 chemical reaction Methods 0.000 claims abstract description 41
- 239000000872 buffer Substances 0.000 claims abstract description 34
- 239000013522 chelant Substances 0.000 claims abstract description 14
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 13
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 46
- 239000007853 buffer solution Substances 0.000 claims description 39
- 239000002738 chelating agent Substances 0.000 claims description 39
- 239000000243 solution Substances 0.000 claims description 26
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims description 23
- 238000012546 transfer Methods 0.000 claims description 23
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 21
- 239000004094 surface-active agent Substances 0.000 claims description 21
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 20
- 238000011033 desalting Methods 0.000 claims description 18
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 18
- 229920000053 polysorbate 80 Polymers 0.000 claims description 18
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 17
- 229940068968 polysorbate 80 Drugs 0.000 claims description 17
- 239000007995 HEPES buffer Substances 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 230000005855 radiation Effects 0.000 claims description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 12
- 229950002026 girentuximab Drugs 0.000 claims description 10
- 229920000136 polysorbate Polymers 0.000 claims description 10
- 229940068965 polysorbates Drugs 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 239000002585 base Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 8
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 229940095064 tartrate Drugs 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 6
- 239000007795 chemical reaction product Substances 0.000 claims description 6
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 6
- 229940049920 malate Drugs 0.000 claims description 6
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 6
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 claims description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 6
- 239000002736 nonionic surfactant Substances 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 239000011347 resin Substances 0.000 claims description 5
- 229920005989 resin Polymers 0.000 claims description 5
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 4
- 150000007942 carboxylates Chemical class 0.000 claims description 4
- 230000001143 conditioned effect Effects 0.000 claims description 4
- 229960000958 deferoxamine Drugs 0.000 claims description 4
- 238000002523 gelfiltration Methods 0.000 claims description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 4
- 229940068977 polysorbate 20 Drugs 0.000 claims description 4
- 229910000288 alkali metal carbonate Inorganic materials 0.000 claims description 3
- 150000008041 alkali metal carbonates Chemical class 0.000 claims description 3
- 125000006413 ring segment Chemical group 0.000 claims description 3
- 238000000163 radioactive labelling Methods 0.000 abstract description 24
- QCWXUUIWCKQGHC-YPZZEJLDSA-N zirconium-89 Chemical compound [89Zr] QCWXUUIWCKQGHC-YPZZEJLDSA-N 0.000 abstract description 5
- 239000000562 conjugate Substances 0.000 description 28
- 239000011535 reaction buffer Substances 0.000 description 28
- 229950009791 durvalumab Drugs 0.000 description 25
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 24
- 229940074404 sodium succinate Drugs 0.000 description 15
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 15
- 239000008362 succinate buffer Substances 0.000 description 14
- 239000012537 formulation buffer Substances 0.000 description 12
- 235000006408 oxalic acid Nutrition 0.000 description 12
- 229910000029 sodium carbonate Inorganic materials 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 238000000746 purification Methods 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 230000009920 chelation Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 108091006905 Human Serum Albumin Proteins 0.000 description 7
- 102000008100 Human Serum Albumin Human genes 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 5
- 238000003908 quality control method Methods 0.000 description 5
- 230000035484 reaction time Effects 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- 239000013020 final formulation Substances 0.000 description 4
- 239000011261 inert gas Substances 0.000 description 4
- GBNDTYKAOXLLID-UHFFFAOYSA-N zirconium(4+) ion Chemical compound [Zr+4] GBNDTYKAOXLLID-UHFFFAOYSA-N 0.000 description 4
- MOIJZWWOFOQFMH-UHFFFAOYSA-M Gentisic acid sodium Chemical compound [Na+].OC1=CC=C(O)C(C([O-])=O)=C1 MOIJZWWOFOQFMH-UHFFFAOYSA-M 0.000 description 3
- 230000001588 bifunctional effect Effects 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- DAWBXZHBYOYVLB-UHFFFAOYSA-J oxalate;zirconium(4+) Chemical compound [Zr+4].[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O DAWBXZHBYOYVLB-UHFFFAOYSA-J 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000002600 positron emission tomography Methods 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 229950004644 sodium gentisate Drugs 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000012879 PET imaging Methods 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 239000000611 antibody drug conjugate Substances 0.000 description 2
- 229940049595 antibody-drug conjugate Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- HBAYEVATSBINBX-UHFFFAOYSA-N n-[5-[acetyl(hydroxy)amino]pentyl]-n'-hydroxy-n'-[5-[[4-[hydroxy-[5-[(4-isothiocyanatophenyl)carbamothioylamino]pentyl]amino]-4-oxobutanoyl]amino]pentyl]butanediamide Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=S)NC1=CC=C(N=C=S)C=C1 HBAYEVATSBINBX-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- -1 Desferrioxamine B squaramide ester Chemical class 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical group [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000048776 human CD274 Human genes 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229950002950 lintuzumab Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000004801 process automation Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 229940051022 radioimmunoconjugate Drugs 0.000 description 1
- 238000011362 radionuclide therapy Methods 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 239000012487 rinsing solution Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940001593 sodium carbonate Drugs 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229910021654 trace metal Inorganic materials 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960001612 trastuzumab emtansine Drugs 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 150000003754 zirconium Chemical class 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/121—Solutions, i.e. homogeneous liquid formulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/534—Production of labelled immunochemicals with radioactive label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Definitions
- the present disclosure relates generally to a process for the synthesis of radiolabelled biological polymers.
- the disclosure relates to a process for the synthesis of 89 Zr radiolabelled biological polymer-chelate agent conjugates. Automation of the process is also described.
- PET Positron Emission Tomography
- 89 Zr Zirconium-89
- 89 Zr has a useful, relatively long, half-life of 78.4 h.
- Vosjan et al. describe a 89 Zr radiolabelling protocol which utilizes 4-(2- hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer at pH 6.8 - 7.2 to achieve radiochemical yields > 85% after incubation for 1 hour at ambient temperature (Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine, Nature Protocols 2010, 5(4), 739-743). However the kinetics of the radiolabelling step were relatively slow.
- HEPES 4-(2- hydroxyethyl)-1-piperazineethanesulfonic acid
- the present disclosure is directed to processes for synthesising radiolabelled biological polymers.
- the processes advantageously exhibit fast reaction kinetics enabling total process time to be reduced. Additionally, the processes can be automated which further reduces total process time.
- the present disclosure provides a process for the synthesis of 89 Zr labelled biological polymers, wherein said process comprises at least the step of combining a biological polymer-chelating agent conjugate with a source of 89 Zr in the presence of a buffer solution comprising polycarboxylate, and wherein said polycarboxylate is capable of forming a chelate ring with 89 Zr, said chelate ring containing six or more ring atoms.
- the buffer solution comprising polycarboxylate comprises one or more of succinate, glutarate, tartrate, malonate, malate, fumarate, oxaloacetate and citrate.
- the buffer solution comprising polycarboxylate consists of, or consists essentially of, one or more of succinate, glutarate, tartrate, malonate, malate, fumarate, oxaloacetate and citrate.
- the buffer solution comprising polycarboxylate consists of, or consists essentially of, succinate.
- the concentration of polycarboxylate buffer is greater than the concentration of any non-carboxylate buffers.
- the concentration of polycarboxylate buffer during the combining is between about 5mM and 1000mM, or between about 5mM and 500mM, or between about 5mM and 200mM, or between about 5mM and 200mM, or between about 5mM and about 150mM, or between about 5mM and about 100mM, or between about 5mM and about 80mM, or between about 5mM and about 50mM, or between about 5mM and about 30mM.
- the concentration of polycarboxylate during the combining is greater than about 5mM, or greater than about 10mM.
- the combining is performed in the substantial absence of 4- (2-hydroxyethyl)-1 -piperazineethanesulfonic acid (HEPES).
- HEPES 4- (2-hydroxyethyl)-1 -piperazineethanesulfonic acid
- the buffer solution comprising polycarboxylate has a pH from about 4 to about 7, preferably from about 5.5 to about 6.5, more preferably about 6.
- the 89 Zr source is derived from 89 Zr oxalate.
- the 89 Zr source is produced by treating 89 Zr oxalate with a base in the presence of the buffer solution comprising polycarboxylate.
- the base may be an alkali metal carbonate, such as sodium carbonate or potassium carbonate.
- the resulting mixture is incubated for about 5 minutes to about 30 minutes, or from about 10 minutes to about 20 minutes.
- the conversion to 89 Zr labelled biological polymer is greater than about 50%, or greater than about 60%, or greater than about 70%, or greater than about 80%, or greater than about 90%, after 15 minutes at 25°C.
- the conversion to 89 Zr labelled biological polymer is greater than about 50%, or greater than about 60%, or greater than about 70%, or greater than about 80%, or greater than about 90%, after 5 minutes at 25°C.
- the chelating agent is selected from DFO-squaramide, DFO*- squaramide, benzyl isothiocyanate-DFO, and benzyl isothiocyanate-DFO*, wherein DFO is desferrioxamine B and DFO* is desferrioxamine*.
- the process comprises:
- the biological polymer-chelating agent conjugate is combined with buffer solution comprising polycarboxylate prior to combining with the source of 89 Zr.
- step (b) the desalting agent is pre-conditioned with a solution comprising radiolytic protectant.
- any one or more vessels, transfer lines and transfer equipment exposed to 89 Zr prior to combining with biological polymer-chelating agent conjugate are treated with buffer solution comprising polycarboxylate and the resulting solution transferred to the first vessel.
- any one or more vessels, transfer lines and transfer equipment exposed to 89 Zr after combining with biological polymer-chelating agent conjugate are treated with buffer solution comprising polycarboxylate and the resulting solution transferred to the second vessel.
- the buffer solution comprising polycarboxylate further comprises one or more surfactants.
- the solution comprising radiolytic protectant further comprises one or more surfactants.
- the one or more surfactants comprise one or more non-ionic surfactants.
- the one or more surfactants comprise one or more polysorbates.
- the one or more polysorbates comprise polysorbate 80.
- the one or more polysorbates comprise polysorbate 20.
- the desalting agent in the second vessel comprises a bed of material through which the crude reaction product from the first vessel is passed.
- the bed of material may comprise gel filtration resin.
- radiation detectors are configured to measure radiation in one or both the first and second vessels.
- the biological polymer comprises one or more of peptide, polypeptide, protein, and antibody.
- the biological polymer is an antibody.
- the biological polymer is Girentuximab.
- the 89 Zr labelled biological polymer is 89 Zr-DFOSq- Girentuximab.
- one or more of the process steps is automated.
- the present disclosure provides a process for the synthesis of 89 Zr labelled biological polymers comprising:
- the buffer solution comprising polycarboxylate comprises one or more of succinate, glutarate, tartrate, malonate, malate, fumarate, oxaloacetate and citrate.
- the buffer solution comprising polycarboxylate consists of, or consists essentially of, succinate.
- the concentration of polycarboxylate buffer is greater than the concentration of any non-carboxylate buffers.
- the concentration of polycarboxylate buffer during the combining is between about 5mM and 1000mM, or between about 5mM and 500mM, or between about 5mM and 200mM, or between about 5mM and about 150mM, or between about 5mM and about 100mM, or between about 5mM and about 80mM, or between about 5mM and about 50mM, or between about 5mM and about 30mM.
- the concentration of polycarboxylate during combining is greater than about 5mM, or greater than about 10mM.
- the combining is performed in the substantial absence of 4- (2-hydroxyethyl)-1 -piperazineethanesulfonic acid (HEPES).
- HEPES 4- (2-hydroxyethyl)-1 -piperazineethanesulfonic acid
- the buffer solution comprising polycarboxylate has a pH from about 4 to about 7, preferably from about 5.5 to about 6.5, more preferably about 6.
- the 89 Zr source is derived from 89 Zr oxalate.
- the 89 Zr source is produced by treating 89 Zr oxalate with a base in the presence of the buffer solution comprising polycarboxylate.
- the base may be an alkali metal carbonate, such as sodium carbonate or potassium carbonate.
- the resulting mixture is incubated for about 5 minutes to about 30 minutes, or from about 10 minutes to about 20 minutes.
- the conversion to 89 Zr labelled biological polymer is greater than about 50%, or greater than about 60%, or greater than about 70%, or greater than about 80%, or greater than about 90%, after 15 minutes at 25°C.
- the conversion to 89 Zr labelled biological polymer is greater than about 50%, or greater than about 60%, or greater than about 70%, or greater than about 80%, or greater than about 90%, after 5 minutes at 25°C.
- the chelating agent is selected from DFO-squaramide, DFO*- squaramide, benzyl isothiocyanate-DFO, and benzyl isothiocyanate-DFO*, wherein DFO is desferrioxamine B and DFO* is desferrioxamine*.
- the biological polymer-chelating agent conjugate is combined with buffer solution comprising polycarboxylate prior to combining with the source of 89 Zr.
- the desalting agent prior to step (b) is pre-conditioned with a solution comprising radiolytic protectant.
- any one or more vessels, transfer lines and transfer equipment exposed to 89 Zr prior to combining with biological polymer-chelating agent conjugate are treated with buffer solution comprising polycarboxylate and the resulting solution transferred to the first vessel.
- any one or more vessels, transfer lines and transfer equipment exposed to 89 Zr after combining with biological polymer-chelating agent conjugate are treated with buffer solution comprising polycarboxylate and the resulting solution transferred to the second vessel.
- the buffer solution comprising polycarboxylate further comprises one or more surfactants.
- the solution comprising radiolytic protectant further comprises one or more surfactants.
- the one or more surfactants comprises one or more non-ionic surfactants.
- the one or more surfactants comprise one or more polysorbates.
- the one or more polysorbates comprise polysorbate 80.
- the one or more polysorbates comprise polysorbate 20.
- the desalting agent in the second vessel comprises a bed of material through which the crude reaction product from the first vessel is passed.
- the bed of material may comprise gel filtration resin.
- radiation detectors are configured to measure radiation in one or both the first and second vessels.
- the biological polymer comprises one or more of peptide, polypeptide, protein, and antibody.
- the biological polymer is an antibody.
- the biological polymer is Girentuximab.
- the 89 Zr labelled biological polymer is 89 Zr-DFOSq- Girentuximab.
- one or more of the process steps is automated.
- the present disclosure provides an 89 Zr labelled biological polymer formed by the process according to any one of the herein disclosed embodiments.
- Advantages of the presently disclosed processes may include one or more of the following:
- Figure 1 is a reaction scheme depicting an 89 Zr radiolabelling process according to embodiments of the present disclosure.
- Figure 2 is a photograph of a radiosynthesiser used to conduct a process according to embodiments of the present disclosure.
- Figure 3 is a plot of radiochemical yield (RCY) vs reaction time.
- Figure 4 illustrates the influence of pH and buffer additives on radioactive residuals in isotope vessel (A) and reaction vessel (B).
- Figure 5 compares radioactivity tracking during automated production using HEPES buffer with no additives and succinate buffer with added polysorbate 80 surfactant.
- Figure 6 illustrates radioactivity traces during an automated radiolabelling process according to embodiments of the present disclosure.
- Figure 7 is a plot of radiochemical yield (RCY) of 89 Zr-DFO-NCS-human I gG 1 vs reaction time in different reaction buffers.
- Figure 8 is a plot of radiochemical yield (RCY) of 89 Zr-DFO*-NCS-humanised lgG1 vs reaction time in different reaction buffers.
- Figure 9 is a plot of radiochemical yield (RCY) of 89 Zr-DFO-Sq-Durvalumab vs reaction time in different reaction buffers.
- Ranges throughout this disclosure, various aspects of the invention can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1 , 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range.
- the present disclosure relates to processes for synthesising radiolabelled biological polymers.
- the processes advantageously exhibit fast reaction kinetics enabling total process time to be reduced. Additionally, the processes can be automated which further reduces total process time.
- an 89 Zr source is treated with antibody-chelating agent conjugate in the presence of buffer solution comprising polycarboxylate. This results in chelation of the antibody-chelating agent to 89 Zr and formation of 89 Zr labelled antibody.
- the labelled antibody is subsequently purified.
- Figure 1 illustrates an overall reaction scheme in which, in a first reaction, an antibody-chelating agent conjugate is prepared by reacting an antibody with a chelating agent.
- the antibody-chelating agent conjugate is subsequently reacted with an 89 Zr source in a succinate buffer (according to the present disclosure) or, alternatively, HEPES buffer (comparative) to form the labelled antibody.
- Exemplary antibodies and antibody-drug conjugates include Trastuzumab, Cetuximab, Panitumumab, Nimotuzumab, Durvalumab, Atezolizumab, Girentuximab, Lintuzumab, Trastuzumab Emtansine, and Brentuximab Vedotin.
- the 89 Zr source utilised in the presently disclosed processes is derived from, for example, zirconium oxalate.
- Oxalate is used to assist in the purification of zirconium (IV) and stabilize the ion in solution, but this oxalate has to be removed prior to preparation of the radiolabelled biological polymer-chelating agent conjugate.
- an aqueous solution of zirconium oxalate in oxalic acid is neutralised with base in the presence of a buffer comprising polycarboxylate.
- the base is an alkali metal base such as sodium carbonate or potassium carbonate.
- 89 Zr source may be derived from alternative zirconium complexes to zirconium oxalate.
- Buffer solution comprising polycarboxylate (reaction buffer)
- a key feature of the presently disclosed processes is performing the radiolabelling step in the presence of a buffer solution comprising polycarboxylate.
- the buffer solution comprising polycarboxylate may also be referred to as ‘reaction buffer’, that is, the buffer in which the chelation of the biological polymer-chelating agent conjugate to 89 Zr occurs (see Figure 1).
- Useful polycarboxylates comprise one or more of succinate, glutarate, tartrate, malonate, malate, fumarate, oxaloacetate and citrate.
- succinate is a preferred polycarboxylate.
- the role of the polycarboxylate is to stabilize the zirconium (IV) ion and facilitate transfer chelation to the biological polymer-chelating agent conjugate.
- Oxalate forms a stable five-membered chelate ring when bound to zirconium (IV).
- polycarboxylates such as succinate, tartrate and malonate are likely to form less stable coordination complexes with zirconium (IV) based of their different chelate ring sizes - the less stable zirconium (IV) complexes will favour transfer chelation to the biological polymer-chelating agent conjugate. That is, oxalate will form complexes with stable five membered chelate rings - whereas succinate, tartrate and malonate, do not.
- the chelation reaction occurs rapidly in polycarboxylate buffer. In embodiments, greater than 90% chelation occurred in 15 minutes at ambient temperature (about 25°C).
- Non-limiting examples of chelators useful in the presently disclosed processes include DFO-squaramide, DFO*-squaramide, benzyl isothiocyanate-DFO, and benzyl isothiocyanate-DFO*, wherein DFO is desferrioxamine B and DFO* is desferrioxamine*.
- the buffer solution comprising carboxylate may also comprise one or more surfactants.
- useful surfactants include non-ionic surfactants such as polysorbates. Those skilled in the art will understand that other non-ionic surfactants can be used as long as they are pharmaceutically acceptable and suitable for administration to patients.
- Embodiments of the present disclosure provide a process for synthesising radiolabelled biological polymers wherein one or more steps of the process is automated.
- the automated process was performed in a disposable cassette based MultiSyn radiosynthesiser (iPHASE Technologies Pty Ltd, Australia).
- FIG. 2 is a photograph of the radiosynthesiser.
- the skilled person will appreciate that the depicted radiosynthesiser is in no way limiting and the presently disclosed processes could be performed in alternative equipment.
- the radiosynthesiser comprised the following major components:
- reactor vessel (3) containing antibody-chelate agent conjugate in polycarboxylate buffer
- GMP-Durvalumab 50 mg/mL was provided by Vetter Pharma-Fert only GmbH & Co. KG, AstraZeneca AB (UK). Desferrioxamine B squaramide ester was provided by TELIX Pharmaceuticals (Australia). Boric acid and sodium chloride were purchased from VWR (Germany). Oxalic acid, 4-(2-hydroxyethyl)-1- piperazineethanesulfonic acid (HEPES), D-trehalose, sodium carbonate, sodium succinate, polysorbate 80 (Tween 80), DMSO, and trifluoroacetic acid (TFA) were purchased from Sigma-Aldrich (Sydney, Australia). Human serum albumin (20%) was purchased from CSL Behring (Australia). Methanol was purchased from Merck (Germany).
- PD-10 desalting columns containing Sephadex G-25 resin were purchased from Cytiva (MA, USA). Sterile free-flex saline bags were purchased from Fresenius Kabi (NSW, Australia). Water-for-injection bags (WFI) were purchased from Baxter (Australia). Buffer solutions were prepared using WFI and stored in sterile vials at 2-8°C.
- Bacterial endotoxin LAL testing kits were purchased from Charles River (Australia). Standard hospital issue 0.22 pm sterile filters, needles, and water-for- injection (WFI) were used. Sterile glass vials were purchased from Huayi Isotopes (Changshu, China). Sterile cassette kits were purchased from iPHASE Technologies (Melbourne, Australia).
- Zirconium-89 was produced at Austin Health (Heidelberg, VIC) via the 89 Y(p,n) 89 Zr reaction using an IBA (Belgium) 18 MeV cyclotron and reconstituted in 0.05 M oxalic acid (Sigma Aldrich, USA, purified grade, 99.999% trace metal basis dissolved in Ultrapur water). Radioactivity was measured using either a Capintec CRC-55t PET dose calibrator (Mirion Technologies Inc., USA) or a Perkin Elmer (USA) Wizard2 automated gamma counter.
- iTLC Instant thin layer chromatography
- SE- HPLC Size-exclusion high performance liquid chromatography
- Protein concentrations were determined via absorbance at 280nm using a NanoDrop Lite spectrophotometer (Thermo Fisher Scientific, USA) in I gG 1 protein mode.
- HEK293 cells transfected with human PD-L1 were cultured in DMEM:F12 media (Gibco) containing 10% fetal calf serum (FCS, Gibco) and 0.4 mg/mL Geneticin (Gibco, G418).
- HCC827 were cultured in RPMI media (Gibco) containing 20% FCS.
- A549 cells were cultured in DMEM:F12 media containing 10% FCS. Culture conditions for all cell lines were 5% CO2 at 37°C.
- Buffer comprising polycarboxylate (reaction buffer)
- Examples according to the present disclosure utilised a reaction buffer comprising polycarboxylate.
- the polycarboxylate was succinate and was employed at concentrations of 20 mM and pH 6.
- the reaction buffer may contain a surfactant.
- the surfactant was polysorbate 20.
- the surfactant was polysorbate 80. Comparative examples utilised HEPES buffer at 0.5 M concentration and pH 7.2. Formulation buffer
- Formulation buffer was prepared using clinical grade saline bags (100 mL) by removing an appropriate amount of saline from the bag (20 mL) under sterile conditions and adding freshly dissolved sodium gentisate (450 mg) in ‘PBS concentrate’ (10 mL) consisting of 24.3 mM KCI, 90 mM Na2HPO4, 16.2 mM KH2PO4, and 0.18% polysorbate 80. This resulted in a sterile bag containing 0.5% sodium gentisate (w/v) and 0.02% polysorbate 80 (w/v) in PBS (90 mL).
- GMP-Durvalumab 50 mg/mL was placed in 8x Amicon Ultra-15 centrifugal filter devices (MWCO 50 kDa) in 50 mg (1 mL) aliquots each. Buffer exchange into borate buffer (0.5 M, pH 9.0) was performed over 3 cycles (9 mL each, 15-25 minutes at 4000 ref) while ensuring the volume in each centrifugal filter did not drop below 1 mL. Following buffer exchange, aliquots were combined and diluted to approx. 10 mg/mL using borate buffer (0.5 M, pH 9.0).
- DFOSqOEt (1018 pL, 10 mg/mL in DMSO, 6 molar equivalents) was then added (final DMSO concentration ⁇ 4%) and the reaction was allowed to stand at ambient temperature (24-26°C) for 22 hours. Equal aliquots of the reaction mixture were then applied to 8x Amicon Ultra-15 centrifugal filter devices (MWCO 50 kDa) and underwent three filtration cycles with buffer comprising polycarboxylate (20 mM sodium succinate, pH 6, 275 mM trehalose, 0.02% polysorbate 80) or HEPES (0.5 M, pH 7.2) (9 mL each, 15-25 minutes at 4000 ref).
- buffer comprising polycarboxylate (20 mM sodium succinate, pH 6, 275 mM trehalose, 0.02% polysorbate 80) or HEPES (0.5 M, pH 7.2) (9 mL each, 15-25 minutes at 4000 ref).
- Radiolabelling kinetics in HEPES (0.5 M, pH 7.2) and sodium succinate (20 mM, pH 6) buffer were compared by neutralizing 89 Zr-oxalate (3.7 MBq) using 0.4 equivalents (v/v) sodium carbonate (0.1 M, pH 10.8), diluting with reaction buffer to give a final reaction volume of 100 pL, followed by addition of varying amounts of DFOSq- Durvalumab. Reactions were incubated at ambient temperature and samples taken at 5, 15, 30, and 60 minutes were analysed by iTLC using citrate (20 mM, pH 5) as a mobile phase.
- Figure 3 illustrates that reactions in HEPES buffer were consistently much slower than reactions in succinate buffer. At 1 pg/MBq the difference in radiochemical yield was most pronounced and quantitative reaction yields of 95.6% ⁇ 0.7% were observed after 15 minutes in succinate buffer compared to only 22.4% ⁇ 2.1 % in HEPES buffer.
- Radioactivity residuals in the 89 Zr isotope vessel were investigated by incubating 89 Zr-oxalate (3 MBq) neutralized with 0.4 equivalents (v/v) sodium carbonate (0.1 M, pH 10.8) and diluted to a final volume of 100 pL using either HEPES (0.5 M, pH 7.2) or 20 mM sodium succinate buffer with varying pH between 4.4 - 7 in a 15 mL Falcon tube for 3 minutes at ambient temperature. Solutions were removed followed by rinsing with the respective formulation buffer (1 mL).
- Radioactivity in the 89 Zr isotope vessels was recorded at the end of incubation, after removal of buffered 89 Zr-oxalate solution, and after the final rinsing step using a dose calibrator. Radioactivity residuals at each step were calculated as fractions of the initial activity in each isotope vessel.
- Figure 4A shows the results of residual radioactivity analyses performed manually with respect to buffer pH and additives for the 89 Zr isotope vessel.
- Residual radioactivity in the reactor vessel may arise from radiolabelled antibody sticking to plastic surfaces.
- a range of different reactor vessel materials including PE, PET, PP, COC, and glass with either flat or conical shapes were investigated, however differences in residual 89 Zr-DFOSq-Durvalumab were minor, and these minor improvements were limited to vial types that were difficult to integrate into the radiosynthesiser flow path. Subsequently, buffer additives such as sodium chloride, polysorbate 80, and human serum albumin (HSA) were examined.
- buffer additives such as sodium chloride, polysorbate 80, and human serum albumin (HSA) were examined.
- Radioactivity residuals in the reactor vessel were investigated by incubating 89 Zr-DFOSq-Durvalumab (5 MBq, > 98% radiochemical purity) formulated in sodium succinate (20 mM, pH 6, 1 mL) containing combinations of 0.15 M NaCI, 0.02% polysorbate 80, and 1 % HSA in reactor vessels for 30 minutes at ambient temperature. Solutions were removed followed by rinsing with formulation buffer (1 mL) containing the respective additives. In each experiment, the radioactivity in the reactor vessel was recorded at the end of incubation, after removal of 89 Zr-DFOSq-Durvalumab solution, and after the final rinsing step using a dose calibrator. Radioactivity residuals at each step were calculated as fractions of the initial activity in each reactor vessel.
- Figure 5 shows a summary of radioactivity residuals before and after optimisation of the automated protocol.
- the total reaction volume was 1.8 mL and activity concentration was approximately 120 MBq/mL.
- syringe (2) contained a mixture of sodium carbonate (0.1 M, pH 10.8) and buffer solution comprising polycarboxylate (reaction buffer; in this example succinate buffer (20 mM, pH 6) containing 0.02% polysorbate 80).
- reaction buffer in this example succinate buffer (20 mM, pH 6) containing 0.02% polysorbate 80.
- the volumes of Na2COs solution (V Na2CO3 ) and buffer solution (V reaction bu ⁇ er ) were determined by the volume of 89 Zr in oxalic acid via the following formulae:
- the 89 Zr isotope vessel (1), syringe (2), and transfer lines were then rinsed with a total of 400 pL reaction buffer from the buffer vessel (7) and transferred to the reactor vessel (3).
- the mixture was allowed to react for 15 minutes at 25°C during which time the desalting bed (4) was automatically conditioned with 30 mL of 0.5% sodium gentisate (w/v) in PBS pH 7.2 + 0.02% polysorbate 80 (w/v) from the formulation buffer vessel (8) using syringe (9).
- the reactor vessel (3) was pressurised with inert gas and contents were loaded onto the desalting bed (4).
- the reactor vessel (3) was rinsed with 400 pL reaction buffer and added to the desalting bed (4).
- the procedure may be stopped if the radiopharmaceutical were to be shipped to other sites.
- the intermediate vial was removed, and an appropriate patient dose dispensed manually into a separate sterile vial which was reconnected to the radiosynthesiser for automated sterile filtration into a patient syringe.
- a vessel containing an appropriate patient dose (92.5 MBq) in 4 mL formulation buffer was reconnected to the intermediate vessel line.
- the patient dose was drawn into syringe (9) and transferred into the patient syringe (7) via a 0.22 pm vented sterile filter followed by an inert gas flush.
- the cassette was washed with formulation buffer and dried with inert gas to minimize cassette residual activity.
- FIG. 6 shows representative radiation profiles of the reactor vessel (left trace) and the purification bed (right trace). Transfers of neutralised 89 Zr solution into the reactor vessel and crude reaction mixture out of the reactor vessel was followed via the reactor vessel radiation detector. Using the purification bed radiation detector, loading of the crude reaction mixture onto the purification bed, removal of leading waste fractions, and product collection was monitored. Based on the purification bed radiation profile, peak intensity was identified as the optimal point to trigger product collection. Appropriate steps were included in the synthesis program allowing for variable elution volumes to adjust for elution profile variability between syntheses. This feature also allowed for facile transfer of the procedure to suit radiolabelling of other conjugated antibodies.
- Radionuclidic identity and purity were confirmed for every production. Sterility and bacterial endotoxin testing showed no positive results over the limit of detection. All productions fulfilled the quality control release criteria for clinical use.
- Immunoreactive fraction was determined as described by Lindmo et al. (Journal of Immunological Methods 1984;72(1):77-89). Briefly, 89 Zr-DFOSq-Durvalumb (20 ng) was incubated with 0-5x10 6 HEK293/PD-L1 cells for 45 minutes at ambient temperature followed by centrifugation (2000 ref for 2 minutes). The supernatant was removed, and the cell pellet was washed with media (1 mL) followed by centrifugation (2000 ref for 2 minutes). Washing steps were repeated a further two times and the radioactivity in the cell pellet was determined using a gamma counter.
- Non-specific binding was determined by incubating 89 Zr-DFOSq-Durvalumb (20 ng) together with Durvalumab (60 pg) following the above protocol. Immunoreactive fraction was calculated by dividing the radioactivity in the washed cell pellet by the average activity of triplicate standards containing 89 Zr-DFOSq-Durvalumb (20 ng).
- 89 Zr in oxalic acid was neutralised using 0.4 eq v/v sodium carbonate (0.1 M, pH 10.8).
- Neutralised 89 Zr (3.7 MBq, 10.4 pL) was added to DFO-NCS-human lgG1 conjugate (7.4 pg, 2 pg/MBq) formulated in either sodium succinate (20 mM, pH 6) or HEPES (0.5 M, pH 7.2) reaction buffer.
- Reaction buffer was added to make up a total reaction volume of 100 pL. Reaction mixtures were incubated at ambient temperature (23-25°C).
- 89 Zr in oxalic acid was neutralised using 0.4 eq v/v sodium carbonate (0.1 M, pH 10.8).
- Neutralised 89 Zr (3.7 MBq, 11.3 pL) was added to DFO*-NCS- humanised lgG1 conjugate (7.4 pg, 2 pg/MBq) formulated in either sodium succinate (20 mM, pH 6) or HEPES (0.5 M, pH 7.2) reaction buffer.
- Reaction buffer was added to make up a total reaction volume of 100 pL. Reaction mixtures were incubated at ambient temperature (23-25°C). Samples for determination of radiochemical yield were taken at 5, 15, 30, and 60 minutes and analysed via iTLC (20 mM citrate pH 5). Reactions were performed in triplicates and results are summarised in Figure 8.
- 89 Zr in oxalic acid was neutralised using 0.4 eq v/v sodium carbonate (0.1 M, pH 10.8).
- Neutralised 89 Zr (3.7 MBq, 4.16 pL) was added to DFO-Sq- Durvalumab conjugate (3.7 pg, 1 pg/MBq) formulated in either sodium succinate (20 mM, pH 6) or HEPES (0.5 M, pH 7.2) reaction buffer.
- Relevant reaction buffer, or mixtures of reaction buffers were added to make up a total reaction volume of 100 pL. Reaction mixtures were incubated at ambient temperature (23-25°C). Samples for determination of radiochemical yield were taken at 5, 15, 30, and 60 minutes and analysed via iTLC (20 mM citrate pH 5). Reactions were performed in triplicates or as single points and results are summarised in Figure 9.
- Example 8 Radiolabelling speed of different immunoconjugates in succinate buffer at clinical specific activities
- 89 Zr in oxalic acid was neutralised using 0.4 eq v/v sodium carbonate (0.1 M, pH 10.8).
- Neutralised 89 Zr was added to immunoconjugate (4.0 - 13.5 pg/MBq) formulated in sodium succinate (20 mM, pH 6) reaction buffer.
- Reaction buffer was added (1.5 eq v/v relative to volume of 89 Zr in oxalic acid) and reaction mixtures were incubated at ambient temperature (23-25°C).
- Samples for determination of radiochemical yield (RCY) were taken at 5 minutes and analysed via iTLC (20 mM citrate pH 5). Reactions were performed in triplicates and results are summarised in Table 2.
- DFOSq-Girentuximab was prepared as per the procedure for DFOSq- Durvalumab in Example 1. Automated radiolabelling with 89 Zr was performed using a similar procedure as in Example 4 to yield 89 Zr-DFOSq-Girentuximab with a process yield of 60% and radiochemical purity >97%.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Dispersion Chemistry (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne des procédés de synthèse de conjugués polymère-chélate biologiques radiomarqués par du zirconium-89. Le radiomarquage est effectué en présence d'un tampon polycarboxylate conduisant à une cinétique de réaction améliorée et à des temps de traitement courts. Les procédés fournissent un degré élevé de reproductibilité, d'excellents rendements radiochimiques et peuvent être automatisés.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/AU2022/050088 WO2023150820A1 (fr) | 2022-02-10 | 2022-02-10 | Procédé de synthèse de polymères biologiques radiomarqués |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/AU2022/050088 WO2023150820A1 (fr) | 2022-02-10 | 2022-02-10 | Procédé de synthèse de polymères biologiques radiomarqués |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023150820A1 true WO2023150820A1 (fr) | 2023-08-17 |
Family
ID=87563325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2022/050088 WO2023150820A1 (fr) | 2022-02-10 | 2022-02-10 | Procédé de synthèse de polymères biologiques radiomarqués |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023150820A1 (fr) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104722510A (zh) * | 2015-03-24 | 2015-06-24 | 福建师范大学 | 一种太阳能电池板智能除尘装置 |
EP3865154A1 (fr) * | 2018-10-10 | 2021-08-18 | Astellas Pharma Inc. | Composition pharmaceutique contenant un complexe de fragment fab d'anticorps au site anti-humain marqué |
-
2022
- 2022-02-10 WO PCT/AU2022/050088 patent/WO2023150820A1/fr unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104722510A (zh) * | 2015-03-24 | 2015-06-24 | 福建师范大学 | 一种太阳能电池板智能除尘装置 |
EP3865154A1 (fr) * | 2018-10-10 | 2021-08-18 | Astellas Pharma Inc. | Composition pharmaceutique contenant un complexe de fragment fab d'anticorps au site anti-humain marqué |
Non-Patent Citations (2)
Title |
---|
C. WICHMANN, S. PONIGER, N. GUO, P. ROSELT, S. RUDD, P. S.DONNELLY, F. HEGI-JOHNSON, M. MACMANUS, A. M. SCOTT: "Fully Automated Radiosynthesis of [89Zr]Zr-DFOSq- Durvalumab for Clinical PET Imaging of PD-L1", EUROPEAN JOURNAL OF NUCLEAR MEDICINE, SPRINGER, BERLIN, HEIDELBERG, DE, vol. 48, Berlin, Heidelberg, DE , pages S220 - S221, XP009548217, ISSN: 0340-6997, Retrieved from the Internet <URL:https://link.springer.com/article/10.1007/s00259-021-05547-1> * |
MEIJS, WE ET AL.: "Evaluation of desferal as a bifunctional chelating agent for labeling antibodies with Zr-89", INTERNATIONAL JOURNAL OF RADIATION APPLICATIONS AND INSTRUMENTATION. PART A. APPLIED RADIATION AND ISOTOPES, vol. 43, no. 12, 1992, pages 1443 - 1447, XP024706984, ISSN: 0883-2889, DOI: https://doi.org/10.1016/0883-2889(92)90170-J * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100729247B1 (ko) | 방사선표지 키트 및 결합 분석 | |
CA3016901C (fr) | Compositions d'immunoglobulines anti-cd45 radio-marquees stabilisees | |
Behr et al. | Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives | |
Sharkey et al. | Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22 | |
AU2011209441B2 (en) | Radioimmunoconjugates and uses thereof | |
Behr et al. | Radioiodination of monoclonal antibodies, proteins and peptides for diagnosis and therapy | |
KR20150092702A (ko) | 방사성 제약 복합체 | |
Visser et al. | Optimal quality 131I-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN | |
Kwon et al. | 64Cu-labeled trastuzumab fab-PEG24-EGF radioimmunoconjugates bispecific for HER2 and EGFR: pharmacokinetics, biodistribution, and tumor imaging by PET in comparison to monospecific agents | |
Price et al. | A comparative evaluation of the chelators H4octapa and CHX-A ″-DTPA with the therapeutic radiometal 90Y | |
US11369701B2 (en) | Ri-labeled humanized antibody | |
Zhou et al. | Labeling single domain antibody fragments with fluorine-18 using 2, 3, 5, 6-tetrafluorophenyl 6-[18F] fluoronicotinate resulting in high tumor-to-kidney ratios | |
Hens et al. | Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with 177Lu: in vitro comparison of acyclic and macrocyclic ligands | |
Qiu et al. | A pretargeted imaging strategy for immune checkpoint ligand PD-L1 expression in tumor based on bioorthogonal Diels-Alder click chemistry | |
Carpenet et al. | Anti-CD20 immunoglobulin G radiolabeling with a 99mTc-tricarbonyl core: in vitro and in vivo evaluations | |
WO2023150820A1 (fr) | Procédé de synthèse de polymères biologiques radiomarqués | |
Nakashima et al. | Development of novel trifunctional chelating agents that enhance tumor retention of radioimmunoconjugates | |
Karczmarczyk et al. | Influence of DOTA chelators on radiochemical purity and biodistribution of 177Lu-and 90Y-Rituximab in xenografted mice | |
Kameswaran et al. | Clinical scale preparation and evaluation of 131I-Rituximab for Non-Hodgkin's Lymphoma | |
EP4317188A1 (fr) | Complexe radioactif d'anticorps anti-egfr, et produit radiopharmaceutique | |
EP4327833A1 (fr) | Agent antitumoral radioactif | |
EP4328244A1 (fr) | Anticorps humanisé marqué par un nucléide émettant un rayonnement ? | |
EP4230637A1 (fr) | Complexes radioactifs d'anticorps anti-her2 et produit radiopharmaceutique | |
JP2024520180A (ja) | ウロキナーゼプラスミノーゲンアクチベーター受容体標的放射性医薬品 | |
Carpenet et al. | Anti-CD20 Immunoglobulin G Radiolabeling With a 99mtc-Tricarbonyl Core |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22925256 Country of ref document: EP Kind code of ref document: A1 |